Results 11 to 20 of about 3,283 (198)

Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations

BMJ Open Ophthalmology
Dual inhibition of the angiopoietin (Ang)/Tie and vascular endothelial growth factor (VEGF) signalling pathways in patients with retinal diseases, such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME), may induce ...
Sanjay Sharma, David T Wong, Shaheer Aboobaker, David Maberley, Pradeepa Yoganathan   +4 more
doaj   +3 more sources

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology, 2023
Ella H Leung, Daniel J Oh, Shannon E Alderson, Joshlynn Bracy, Mia McLeod, Litzi I Perez, Alexander Bottini, David Chin Yee, Krishna Mukkamala Georgia Retina, Atlanta, GA, USACorrespondence: Ella H Leung, 833 Campbell Hill St NW, Suite 300, Marietta, GA,
Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, Bottini A, Chin Yee D, Mukkamala K   +8 more
doaj   +1 more source

Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema [PDF]

Ophthalmology Retina
Purpose: To compare anatomic biomarkers on spectral-domain OCT between faricimab, a dual angiopoietin-2 (Ang-2)/VEGF-A inhibitor, and aflibercept in a pooled analysis of results from the YOSEMITE/RHINE trials in diabetic macular edema (DME).
Jennifer I. Lim, Manuel J. Amador, D. Dhoot, Avni P. Finn, S. Fraser-bell, Kara Gibson, O. Idowu, Rahul N. Khurana, P. Lanzetta, Tai-Chi Lin, Florie Mar, A. Pollreisz, Aleksandra V. Rachitskaya, P. Schlottmann, Yannan Tang, Timothy Y. Y. Lai   +15 more
semanticscholar   +2 more sources

Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials

Ophthalmology Science
Purpose: To compare the effect of faricimab, a dual angiopoietin-2 (Ang-2) and VEGF-A inhibitor, with aflibercept on resolution of hyperreflective foci (HRF) in patients with diabetic macular edema (DME).
Usha Chakravarthy, FRCOphth, PhD, Varun Chaudhary, MD, FRCS(C), Srinivas R. Sadda, MD, Colin S. Tan, FRCOphth, FRCSEd (Ophth), Stela Vujosevic, MD, PhD, Sascha Fauser, MD, Kara Gibson, PhD, Carl Glittenberg, MD, Nancy Holekamp, MD, FASRS, Ben Lanza, PhD, Andreas Maunz, PhD, Jeffrey R. Willis, MD, PhD, Rishi P. Singh, MD   +12 more
doaj   +2 more sources

Clinical Outcomes Following a Switch of Therapy to Faricimab in Patients Affected by Neovascular Age-Related Macular Degeneration [PDF]

Journal of Clinical Medicine
Objectives: In this study, we evaluated clinical outcomes following a therapy switch to Faricimab, in a patient cohort affected by neovascular age-related macular degeneration (nAMD), having received prior intravitreal anti-VEGF therapy.
P. Wolfrum, E. W. Böhm, Katrin Lorenz, B. Stoffelns, N. Pfeiffer, C. Korb   +5 more
semanticscholar   +3 more sources

Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME

International Journal of Retina and Vitreous
Management of vitreoretinal disorders (e.g., neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME]) have assumed the standard therapy of lifelong anti-VEGF injections with drugs like aflibercept, brolucizumab, ranibizumab ...
Fernando M Penha, Maliha Masud, Zoha A. Khanani, Mathew Thomas, Rodney D. Fong, Kyler Smith, Avishay Chand, Majid Khan, Greggory Gahn, Gustavo Barreto Melo, Arshad M. Khanani   +10 more
doaj   +2 more sources

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study [PDF]

Eye
The Faricimab Real-World Evidence (FARWIDE) studies are evaluating real-world outcomes of eyes with diabetic macular oedema (DMO)/neovascular age-related macular degeneration (nAMD) treated with faricimab in the UK.
T. Peto, I. Pearce, J. Talks, G. de Salvo, Praveen J. Patel, S. D. De Silva, Richard P. Gale, S. Sivaprasad, Deepali Varma, Rhianon Reynolds, C. Bailey, L. Downey, C. Kiire, Gloria C. Chi, M. Dodds, N. James, Amanda Downey, Parul Dayal   +17 more
semanticscholar   +2 more sources

Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration.

Ophthalmic Surgery Lasers and Imaging Retina
BACKGROUND AND OBJECTIVE This study assessed treatment patterns and early outcomes among patients with neovascular age-related macular degeneration (nAMD) initiating faricimab in routine clinical practice in the United States.
Ferhina S. Ali, D. Tabano, Durga S. Borkar, Theodore Leng, Vincent Garmo, Ayesha Ahmed, Rachel Myers, Jacqueline K. Shaia, Giulio Barteselli, Rishi P. Singh   +9 more
semanticscholar   +2 more sources

Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison [PDF]

Drug Target Insights
Objectives: To assess through an indirect treatment comparison (ITC) the potential benefit of faricimab over the anti-vascular endothelial growth factor (VEGF) real-life scenario, hereby defined standard of care (SoC), in Italy, that is, aflibercept ...
Carlotta Galeone, Federica Turati, Massimo Nicolò, Mariacristina Parravano, Stela Vujosevic, Laura Bianchino, Emilia Sicari, Paolo Lanzetta   +7 more
doaj   +4 more sources

Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema

Ophthalmology and Therapy
Introduction This study aimed to assess the morphological and functional effects of faricimab in patients with chronic diabetic macular edema (DME) who had an insufficient response to previous treatments.
Viktoria Deiters, Anna Lorger, Franziska Eckardt, Jakob Siedlecki, Benedikt Schworm, Siegfried G. Priglinger, Tina R. Herold   +6 more
doaj   +2 more sources